content: <HTML><HEAD>
  <TITLE>Form 8-K</TITLE>
  </HEAD>
   <BODY BGCOLOR="WHITE">
  
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4" COLOR="#000000"><B>SECURITIES
  AND EXCHANGE COMMISSION </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>WASHINGTON, D.C. 20549 </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
  SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"
  COLOR="#000000"><B>FORM 8-K </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>CURRENT REPORT
  </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of Report (Date of earliest event reported): April 17, 2003 </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P
  STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>CONCEPTUS, INC.<U></U> </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"
  COLOR="#000000"><B>(Exact name of registrant as specified in charter) </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Delaware</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>incorporation or
  organization)</B></FONT></P></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>000-27596</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission file number)</B></FONT></P></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>94-3170244</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(I.R.S. employer<BR>identification no.)</B></FONT></P></TD></TR>
  </TABLE><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>1021
  Howard Avenue </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>San Carlos, CA 94070 </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices) (Zip code) </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Registrant&#146;s telephone number, including area code: (650) 628-4700 </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR
  WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>ITEM
  5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On April 17, 2003,
  Conceptus, Inc. issued a press release announcing that Mark M. Sieczkarek has been appointed president and chief executive officer and a member of the board of directors, effective immediately. Text of the press release follows: </FONT></P><P
  STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SAN CARLOS, Calif. (April 17, 2003)&#151;Conceptus, Inc. (Nasdaq: CPTS),
  </B>developer of the non-incisional permanent birth control procedure <I>Essure<FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></I><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000">, today announced that Mark M. Sieczkarek, 48, has been appointed president and chief executive officer and a member of the board of directors, effective immediately. </FONT></FONT></P><P
  STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Mr. Sieczkarek comes to Conceptus with extensive experience in general
  management, marketing, finance and corporate development. Most recently, Mr. Sieczkarek served as President, Americas, of Bausch and Lomb, Inc. (NYSE: BOL), where he led the region to double-digit revenue and profitability growth. Bausch and Lomb is
  an eye healthcare company with annual revenues of over $1.8 billion. His prior positions at Bausch and Lomb include President, Europe, Middle East and Africa, where he oversaw the introduction of the Zyoptix laser for LASIK eye surgery. He also held
  several financial and corporate development positions, playing a key role in negotiating four major strategic acquisitions in the surgical segment that added over $400 million to Bausch and Lomb&#146;s revenue base. Mr. Sieczkarek has also held
  general management positions at KOS Pharmaceuticals and Bristol-Myers Squibb, where he was involved in the early commercialization of several new products. Mr. Sieczkarek has a B.S. degree from the State University of New York at Buffalo and an MBA
  from Canisius College. </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;Mark Sieczkarek is a seasoned life
  science executive with extensive experience commercializing medical products, both drugs and devices,&#148; stated Kathryn Tunstall, Chairman of the Board of Conceptus. &#147;In addition to his demonstrated ability to consistently improve financial
  performance in his areas of responsibility, Mark brings in-depth knowledge and extensive experience in both professional and consumer marketing,&#148; Ms. Tunstall added. &#147;We are delighted that Mark is joining Conceptus and feel confident that
  his skill set, along with his dedication to principled leadership will serve our customers and stockholders well,&#148; she added. </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P
  STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Commenting on his appointment, Mr. Sieczkarek stated, &#147;I am extremely excited to be joining a company with a product that will set a new standard of
  care in women&#146;s health. <I>Essure</I> is an extraordinary product ready for wide-scale commercialization and I welcome the opportunity to lead an outstanding organization in bringing a non-incisional alternative for permanent birth control to
  women in the U.S. and worldwide.&#148; </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">As previously announced,
  Steven Bacich, who served as president and chief executive officer since January 2000, will assist in the transition with primary responsibility over research and development, business development and clinical and medical affairs. As part of this
  transition, Mr. Bacich resigns from his position as a member of the board of directors. &#147;We are delighted that Steve Bacich will continue to contribute his strong talents to the company,&#148; stated Ms. Tunstall. &#147;Steve is a recognized
  expert in women&#146;s health and has demonstrated his ability to bring a major medical innovation to the market with good science, excellent clinical results and in record time,&#148; she added. </FONT></P><P
  STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">2 </FONT></P>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About
  </B><B><I>Essure</I></B><B> </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B></B><I>Essure</I> deploys a
  soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or
  blockage in the fallopian tube. An <I>Essure</I> procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is expected to return home about 45 minutes
  after the procedure is completed. </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About Conceptus
  </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Conceptus, Inc. manufactures and markets <I>Essure</I>,
  which is designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. The availability of <I>Essure</I> in the U.S. is expected to open up a market currently occupied by surgical tubal ligation and
  vasectomy, which combined account for over 1 million procedures annually in the United States. </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and
  uncertainties. Clinical efficacy of and market demand for our product and the results of our marketing programs, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking
  statements. Such differences may be based upon factors within the Company&#146;s control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company&#146;s control, such as
  decisions by regulatory authorities and insurance carriers, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended
  December&nbsp;31, 2002 and other filings with the Securities and Exchange Commission </I></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">3 </FONT></P>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SIGNATURES
  </B></FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV
  STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="37%"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">CONCEPTUS, INC.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">(Registrant)</FONT></P></TD></TR>
  <TR>
  <TD HEIGHT="16"></TD></TR>
  <TR>
  <TD VALIGN="top" WIDTH="2%"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></P></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" WIDTH="37%"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>LEN</SMALL> K.
  F<SMALL>URUTA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
  <TR>
  <TD><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
  <TR>
  <TD><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" NOWRAP WIDTH="37%"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Glen K. Furuta</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000">Vice President, Finance &amp; Administration</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">and Chief Financial
  Officer</FONT></P></TD></TR>
  </TABLE></DIV><P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">Dated:&nbsp;&nbsp;April 18, 2003 </FONT></P>
  </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 16059}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "03655755"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Form 8-K
  SECURITIES
  AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported): April 17, 2003
  CONCEPTUS, INC.
  (Exact name of registrant as specified in charter)
  Delaware
  (State or other jurisdiction of
  incorporation or
  organization)
  000-27596
  (Commission file number)
  94-3170244
  (I.R.S. employer
  identification no.)
  1021
  Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code: (650) 628-4700
  ITEM
  5.    OTHER EVENTS.
  On April 17, 2003,
  Conceptus, Inc. issued a press release announcing that Mark M. Sieczkarek has been appointed president and chief executive officer and a member of the board of directors, effective immediately. Text of the press release follows:
  SAN CARLOS, Calif. (April 17, 2003)—Conceptus, Inc. (Nasdaq: CPTS),
  developer of the non-incisional permanent birth control procedure
  Essure
  ™
  , today announced that Mark M. Sieczkarek, 48, has been appointed president and chief executive officer and a member of the board of directors, effective immediately.
  Mr. Sieczkarek comes to Conceptus with extensive experience in general
  management, marketing, finance and corporate development. Most recently, Mr. Sieczkarek served as President, Americas, of Bausch and Lomb, Inc. (NYSE: BOL), where he led the region to double-digit revenue and profitability growth. Bausch and Lomb is
  an eye healthcare company with annual revenues of over $1.8 billion. His prior positions at Bausch and Lomb include President, Europe, Middle East and Africa, where he oversaw the introduction of the Zyoptix laser for LASIK eye surgery. He also held
  several financial and corporate development positions, playing a key role in negotiating four major strategic acquisitions in the surgical segment that added over $400 million to Bausch and Lomb's revenue base. Mr. Sieczkarek has also held
  general management positions at KOS Pharmaceuticals and Bristol-Myers Squibb, where he was involved in the early commercialization of several new products. Mr. Sieczkarek has a B.S. degree from the State University of New York at Buffalo and an MBA
  from Canisius College.
  "Mark Sieczkarek is a seasoned life
  science executive with extensive experience commercializing medical products, both drugs and devices," stated Kathryn Tunstall, Chairman of the Board of Conceptus. "In addition to his demonstrated ability to consistently improve financial
  performance in his areas of responsibility, Mark brings in-depth knowledge and extensive experience in both professional and consumer marketing," Ms. Tunstall added. "We are delighted that Mark is joining Conceptus and feel confident that
  his skill set, along with his dedication to principled leadership will serve our customers and stockholders well," she added.
  Commenting on his appointment, Mr. Sieczkarek stated, "I am extremely excited to be joining a company with a product that will set a new standard of
  care in women's health.
  Essure
  is an extraordinary product ready for wide-scale commercialization and I welcome the opportunity to lead an outstanding organization in bringing a non-incisional alternative for permanent birth control to
  women in the U.S. and worldwide."
  As previously announced,
  Steven Bacich, who served as president and chief executive officer since January 2000, will assist in the transition with primary responsibility over research and development, business development and clinical and medical affairs. As part of this
  transition, Mr. Bacich resigns from his position as a member of the board of directors. "We are delighted that Steve Bacich will continue to contribute his strong talents to the company," stated Ms. Tunstall. "Steve is a recognized
  expert in women's health and has demonstrated his ability to bring a major medical innovation to the market with good science, excellent clinical results and in record time," she added.
  2
  About
  Essure
  Essure
  deploys a
  soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or
  blockage in the fallopian tube. An
  Essure
  procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is expected to return home about 45 minutes
  after the procedure is completed.
  About Conceptus
  Conceptus, Inc. manufactures and markets
  Essure
  ,
  which is designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. The availability of
  Essure
  in the U.S. is expected to open up a market currently occupied by surgical tubal ligation and
  vasectomy, which combined account for over 1 million procedures annually in the United States.
  Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and
  uncertainties. Clinical efficacy of and market demand for our product and the results of our marketing programs, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking
  statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as
  decisions by regulatory authorities and insurance carriers, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended
  December 31, 2002 and other filings with the Securities and Exchange Commission
  3
  SIGNATURES
  Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  CONCEPTUS, INC.
  (Registrant)
  By:
  /
  S
  /    G
  LEN
  K.
  F
  URUTA
  Glen K. Furuta
  Vice President, Finance & Administration
  and Chief Financial
  Officer
  Dated:  April 18, 2003